GlobeNewswire by notified

Ultimovacs ASA: Third quarter 2021 result presentation

Share

Oslo, 11November 2021: Ultimovacs ASA ("Ultimovacs") (OSE ULTI), a clinical stage leader in immune stimulatory vaccines for cancer, announces its third quarter 2021 results today. The presentation by the company's management team will take place at Oslo Cancer Cluster Innovation Park (Ullernchausséen 64) in Jónas Einarsson Auditorium (2nd floor, entrance 2B) at 09:00 CET.

The presentation can also be followed as a live webcast and will be made available on the website. It will be possible to post questions during the presentation through the webcast.

Highlights for the third quarter of 2021:

  • On 26 October 2021, Ultimovacs announced that UV1, will be investigated in a Phase II clinical trial in combination with pembrolizumab in non-small cell lung cancer (NSCLC). The LUNGVAC trial will be a multi-center, randomized, open-label trial which will be sponsored by Drammen Hospital, a leading oncology research center in Norway. The trial will enroll approximately 138 patients and will be conducted at 8-10 clinical centers in Norway. (post quarter event)
  • On 13 October, Ultimovacs announced that the overall survival rate after two years of follow-up in the Phase I clinical trial of UV1 combined with pembrolizumab was 80% in this first cohort of 20 patients. As previously announced, median progression free survival for these patients was 18.9 months. (post quarter event)
  • Results from the 10 patients in cohort 2 of the same trial released on 12 August also showed strong safety and efficacy data after one year (60% objective response, 30% complete response, 90% overall survival and median progression-free survival not reached), reinforcing the cohort 1 data presented at ASCO. (also presented in the Q2-report)
  • On 20 October 2021, Ultimovacs ASA announced that UV1, in combination with checkpoint inhibitors has received Fast Track designation from the U.S. FDA in the treatment of unresectable or metastatic melanoma – either as add-on therapy to pembrolizumab or as add-on therapy to ipilimumab. (post quarter event)
  • INITIUM trial: 91 patients enrolled to date compared to 68 patients in the previous quarterly report.
  • NIPU trial: 45 patients enrolled to date compared to 38 patients in the previous quarterly report.
  • FOCUS trial: The first patient was enrolled on 4 August 2021, and 5 patients have been enrolled to date.
  • DOVACC trial: Regulatory approval is in place and the first patient is expected to be enrolled during Q4 2021.
  • TENDU trial: The Drug Safety Monitoring Board found no safety concerns related to the first cohort of three patients at the 40 μg dose, enabling the trial to advance with enrollment of patients in the second cohort at the 400 μg dose. In total, 4 patients have been enrolled to date.
  • COVID-19: The effect of the pandemic on the biotech industry and the general ability to conduct clinical trials is still uncertain and dependent on the speed of return to a more normal situation. Ultimovacs continues to monitor the impact from COVID-19 on its clinical trials and will update the guidance for INITIUM and our investigator-initiated Phase II trials in our Q4 2021 report. Enrollment updates will continue to be provided in each quarterly report.
  • A private placement was successfully completed on 26 October 2021, raising gross proceeds of MNOK 270. (post quarter event)
  • Total operating expenses amounted to MNOK 42.5 in Q3-21, and MNOK 112.9 YTD.
  • Cash flow from operations was MNOK -32.7 in Q3-21, and MNOK -92.0 YTD. Total cash and cash equivalents were reduced by MNOK32.9 during Q3-21 and amounted to MNOK 347.8 as per 30 September 2021.

The report and presentation are also available on the Company website:

www.ultimovacs.com/investors/reports-and-presentations

For further information, please visit www.ultimovacs.com or contact:

Carlos de Sousa, CEO
Email: carlos.desousa@ultimovacs.com
Phone: +47 908 92507

Hans Vassgård Eid, CFO
Email: hans.eid@ultimovacs.com
Phone: +47 482 48632

Mary-Ann Chang, LifeSci Advisors
Email: mchang@lifesciadvisors.com
Phone: +44 7483 284 853

This information is considered to be inside information pursuant to the EU Market Abuse Regulation and is subject to the disclosure requirements pursuant to Section 5-12 in the Norwegian Securities Trading Act.

This stock exchange announcement was published by Joachim Midttun, Finance Manager at Ultimovacs ASA, on 11November, 2021 at 08:00 CET.


Attachments

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

OTC Markets Group udpeger SEB som OTCQX-sponsor6.7.2022 19:23:09 CEST | pressemeddelelse

NEW YORK, July 06, 2022 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), der er operatør på de finansielle markeder for 12.000 amerikanske og globale værdipapirer, meddelte, at Skandinaviska Enskilda Banken AB (SEB), en førende nordeuropæisk finanskoncern, er blevet udpeget som OTCQX-sponsor. SEB er blevet godkendt af OTC Markets Group til at fungere som sponsor for virksomheder, der skal børsnoteres på OTCQX- og OTCQB-markederne. "OTC Markets Group er begejstret over at kunne inkludere SEB i vores fællesskab af OTCQX-sponsorer," siger Joe Coveney, VP for International Corporate Services hos OTC Markets Group. "Som en førende institutionel bank i Norden vil SEB kunne bidrage med kritisk ekspertise og indsigt til de globale udstedere, der søger at få adgang til amerikanske investorer via vores OTCQX- og OTCQB-markeder." "Det er en stor glæde for SEB at være den første OTCQX-godkendte nordeuropæiske banksponsor, og vi har til hensigt at tilbyde vores børsnoterede nordiske kunder

OTC Markets Group utpeker SEB som OTCQX-sponsor6.7.2022 19:23:09 CEST | Pressemelding

NEW YORK, July 06, 2022 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operatør av finansmarkeder for 12 000 amerikanske og globale verdipapirer, har kunngjort at Skandinaviska Enskilda Banken AB (SEB), et ledende nordeuropeisk finanskonsern, er blitt utpekt som OTCQX-sponsor. SEB er godkjent av OTC Markets Group til å fungere som sponsor for selskaper som skal noteres på OTCQX- og OTCQB-markedene. «OTC Markets Group gleder seg over å inkludere SEB i vårt fellesskap av OTCQX-sponsorer», sa Joe Coveney, visedirektør for International Corporate Services i OTC Markets Group. «Som en ledende institusjonell bank i Norden kan SEB tilby viktig ekspertise og innsikt til globale utstedere som ønsker å få tilgang til amerikanske investorer via våre OTCQX- og OTCQB-markeder.» «SEB gleder seg over å være den første OTCQX-godkjente nordeuropeiske banksponsoren, og vi har til hensikt å tilby våre børsnoterte nordiske kunder muligheter for krysshandel på OTCQX eller OTCQB», sa Micael Ljung

OTC Markets Group utser SEB som OTCQX-sponsor6.7.2022 19:23:09 CEST | Pressemelding

NEW YORK, July 06, 2022 (GLOBE NEWSWIRE) -- OTC Markets Group Inc. (OTCQX: OTCM), operatör på finansmarknaderna för 12 000 amerikanska och globala värdepapper, meddelar att Skandinaviska Enskilda Banken AB (SEB), en ledande nordeuropeisk koncern för finansiella tjänster, har utsetts till OTCQX-sponsor. SEB är godkänt av OTC Markets Group att agera som sponsor för företag som ska börsnoteras på OTCQX- och OTCQB-marknaderna. ”OTC Markets Group är glada över att SEB nu ingår i vår grupp av OTCQX-sponsorer”, säger Joe Coveney, Vice President, International Corporate Services på OTC Markets Group. ”Som en ledande institutionell bank i Norden kommer SEB att tillhandahålla viktig expertis och insikt till globala emittenter som vill nå amerikanska investerare via våra OTCQX- och OTCQB-marknader.” ”SEB är mycket glada över att vara den första nordiska banken som godkänts som OTCQX-sponsor och vi har avsikt att erbjuda våra börsnoterade nordiska kunder möjligheten till korshandel på OTCQX eller

Feedzai Recognized as a Top Anti-Money Laundering Solution by Leading Analyst Firm6.7.2022 16:15:06 CEST | Press release

SAN MATEO, Calif., July 06, 2022 (GLOBE NEWSWIRE) -- Feedzai, the world’s first RiskOps platform for financial risk management, has been ranked among the top vendors in anti-money laundering (AML) in a Forrester report released today, “The Forrester WaveTM: Anti-Money-Laundering Solutions, Q3 2022”. “Feedzai leverages machine learning and automation to overcome the difficulty many institutions have with legacy AML programs which operate with siloed, disparate systems creating a pixelated view of risk,” said Pedro Barata, CPO at Feedzai. “We believe our continued investment in R&D alongside our unified RiskOps-based approach across AML is why we are consistently endorsed by customers and are a strong performer in the Forrester Wave report.” In the last year, Feedzai’s AML suite has helped customers monitor over 200 territories with over 90% precision for high-priority alerts. Findings in The Forrester WaveTM Anti-Money-Laundering Solutions report Feedzai received the highest possible sc

DFDS UDNÆVNER NY HEAD OF FERRY DIVISION6.7.2022 15:30:00 CEST | pressemeddelelse

INVESTOR NEWS nr. 18 - 6. juli 2022 Mathieu Girardinudnævnt til Head of Ferry DivisionMathieu Girardinefterfølger Peder Gellert Pedersen, som går på pension 1.august 2022 Mathieu Girardin er udnævnt til Head of Ferry Division, EVP, og medlem af Executive Management Team (EMT). Han tiltræder DFDS i oktober 2022. "Jeg er glad for at byde velkommen til Mathieu Girardin, som bringer en fremragende blanding af drifts- og ledelseskompetencer til DFDS’ fortsatte vækstrejse," siger Torben Carlsen, CEO for DFDS. “Jeg ser med begejstring frem til at blive en del af DFDS. En stærk motivation for mig er at videreudvikle DFDS’ pålidelige, effektive færgenetværk og services til kunder, samtidig med at DFDS transformeres til en grøn færgevirksomhed,” siger Mathieu Girardin. Mathieu Girardin, fransk statsborger født i 1982, er i øjeblikket Senior Vice President hos CMA CGM, en af ​​verdens største shipping- og logistikvirksomheder, for Short Sea Lines Europe og Containerships. Han har haft ledende sti